• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Comparison of outcomes of radical prostatectomy with and without adjuvant pelvic irradiation in patients with pathologic stage C (T3N0) adenocarcinoma of the prostate.

作者信息

Petrovich Z, Lieskovsky G, Langholz B, Bochner B, Formenti S, Streeter O, Skinner D G

机构信息

Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033, USA.

出版信息

Am J Clin Oncol. 1999 Aug;22(4):323-31. doi: 10.1097/00000421-199908000-00001.

DOI:10.1097/00000421-199908000-00001
PMID:10440184
Abstract

Patients with localized adenocarcinoma of the prostate gland (CaP) are frequently (approximately 50%) found at radical prostatectomy to have extracapsular disease or positive surgical margins. The management of these patients is a subject of controversy because some question the impact of this manifestation of CaP on patient survival or disease-free survival. Between 1976 and 1991, 241 patients with pathologic stage C (T3N0) were treated in this medical center. Of these 241 patients, 201 (83%) received a planned postoperative pelvic irradiation consisting of 48 Gy given to the prostatic fossa, whereas 40 (17%) patients were treated with radical prostatectomy alone. The two study urologists selected these patients not to receive postoperative irradiation based on intraoperative findings and important prognostic factors. Comparison of treatment outcomes in these two treatment groups is a subject of this report. The 201 patients treated with surgery-radiotherapy (S+RT) combination had a higher pathologic stage, greater incidence of seminal vesicle involvement, p = 0.002, and higher mean and median preoperative prostate-specific antigen level, p < 0.0001, than the 40 surgery (S) alone patients. There was no significant difference in the incidence of higher Gleason's score by the treatment group, p = 0.14. In univariate analysis, there was no significant difference in survival, disease-free survival, and time to failure between the two treatment groups. In multivariate analysis after controlling for pathologic stage and Gleason's score, the 201 adjuvant radiotherapy patients were predicted to have recurrence at 68% (95% confidence interval 39%-118%) the rate of the 40 surgery-alone patients. Local recurrence with or without metastatic disease was found in 10% of surgery-alone patients as compared to 5% in those also receiving postoperative irradiation. Treatment tolerance was very good with minor radiotherapy complications only. There was no significant difference in the incidence of incontinence between the two treatment arms. In summary: (a) The use of moderate-dose postoperative radiotherapy was of low toxicity and it did not increase the incidence of incontinence. (b) Local recurrence was 5% in S+RT and 10% in S-alone patients. (c) In multivariate analysis, S+RT patients had 68% rate of recurrence of S-alone patients. (d) Adjuvant RT probably reduces the risk of recurrence in patients with poor prognostic factors. (e) These data need to be interpreted with caution because of the nonrandomized nature of the study.

摘要

相似文献

1
Comparison of outcomes of radical prostatectomy with and without adjuvant pelvic irradiation in patients with pathologic stage C (T3N0) adenocarcinoma of the prostate.
Am J Clin Oncol. 1999 Aug;22(4):323-31. doi: 10.1097/00000421-199908000-00001.
2
Nonrandomized comparison of surgery with and without adjuvant pelvic irradiation for patients with pT3N0 adenocarcinoma of the prostate.前列腺pT3N0腺癌患者接受辅助盆腔放疗与未接受辅助盆腔放疗的手术非随机对照研究。
Am J Clin Oncol. 2001 Dec;24(6):537-46. doi: 10.1097/00000421-200112000-00002.
3
Surgery with adjuvant irradiation in patients with pathologic stage C adenocarcinoma of the prostate.
Cancer. 1995 Nov 1;76(9):1621-8. doi: 10.1002/1097-0142(19951101)76:9<1621::aid-cncr2820760919>3.0.co;2-o.
4
Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate.前列腺病理分期为C期(T3)的患者行根治性前列腺切除术及术后放疗。
Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):139-47. doi: 10.1016/s0360-3016(97)00488-4.
5
Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.对于具有不良病理特征的前列腺癌患者,根治性前列腺切除术后辅助放疗可改善生化结局。
Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):714-24. doi: 10.1016/j.ijrobp.2004.06.018.
6
Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?前列腺癌根治术后切缘阳性和/或病理T3期腺癌且术后前列腺特异性抗原检测不到:是否进行放疗?
Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):674-80. doi: 10.1016/s0360-3016(01)02677-3.
7
Adjuvant radiotherapy in patients with pathologic Stage C (pT3N0) adenocarcinoma of the prostate.
Urology. 1999 Jun;53(6):1184-93. doi: 10.1016/s0090-4295(99)00011-4.
8
Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer.单纯手术与手术联合辅助放疗治疗pT3N0期前列腺癌的比较。
BJU Int. 2002 Apr;89(6):604-11. doi: 10.1046/j.1464-410x.2002.02698.x.
9
Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer.423例pT3N0前列腺癌患者的术后放疗
Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):600-9. doi: 10.1016/s0360-3016(02)02766-9.
10
Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.T1-2期前列腺癌:根治性前列腺切除术后影响生化及临床失败因素的多变量分析
Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52. doi: 10.1016/s0360-3016(96)00590-1.

引用本文的文献

1
Radical prostatectomy for the patient with locally advanced prostate cancer.
Curr Urol Rep. 2003 Jun;4(3):196-204. doi: 10.1007/s11934-003-0069-0.
2
Locally advanced prostate cancer.局部晚期前列腺癌
Curr Treat Options Oncol. 2001 Oct;2(5):403-11. doi: 10.1007/s11864-001-0045-1.